The inflammation scores and fibrosis scores in the group TNBS and MSOND groups are higher than the blank group and ASOND groups (P < 0.05). And the inflammation scores and fibrosis scores in the group drug discovery ASOND I and III are higher than the blank group and the group ASOND II (P < 0.05). The group ASOND II's inflammation score
is only higher than the blank group (P < 0.05). And it is no significant to compare the fibrosis scores between the group ASOND II and the blank group (P > 0.05). 3. The contents of IL-1B, TNF-α and Col-IIIα1 mRNA of the mice colon tissue in the group TNBS and MSOND groups are more than the blank group and ASOND groups (P < 0.05), while the contents of the group ASOND I and III are higher than the blank group and the group ASOND II. The contents of IL-1B and TNF-α mRNA in the group ASOND II is only higher than the blank group. It is no significant to compare the Col-IIIα1 between the
group ASOND and blank group (P > 0.05) 4. The protein contents of NF-κB p65, TGF-β1 of the mice colon tissue in MK-1775 solubility dmso the group TNBS and MSOND groups are higher than the blank group and ASOND groups (P < 0.05). The protein content in the ASOND II is less than the group ASOND I and III, and only higher than the blank group (P < 0.05). Conclusion: 1. It confirms that TNBS induces the animal model of chronic intestinal
fibrosis by observing the disease activity index, colon gross medchemexpress specimens, colonic pathology and fibrosis of the mice of the TNBS group. 2. It is effective to cure the mice of colonic inflammation and fibrosis with NF-κBp65 ASOND for two weeks. The effects are different for the intervention times. The medication effect is the best in the third and fourth weeks. 3. The NF-κBp65 ASOND reduces the inflammation and fibrosis of the colon in mice by decrease the proinflammatory cytokines like TNF-a, IL-1β and Col- III α1′s mRNA contents and NF-κBp65 and TGF-β1′s protein contents. The NF-κBp65 ASOND could be a new effective drug for IBD therapy. On the other hand, the NF- κBp65 MSOND has no above therapy function. Key Word(s): 1. IBD; 2. TNBS; 3. NF-kb; 4.